DrugPatentWatch Database Preview
TALZENNA Drug Profile
When do Talzenna patents expire, and what generic alternatives are available?
Talzenna is a drug marketed by Pfizer Inc and is included in one NDA. There are four patents protecting this drug.
This drug has sixty-eight patent family members in twenty-seven countries.
The generic ingredient in TALZENNA is talazoparib tosylate. Two suppliers are listed for this compound. Additional details are available on the talazoparib tosylate profile page.
Summary for TALZENNA
| International Patents: | 68 |
| US Patents: | 4 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 2 |
| DailyMed Link: | TALZENNA at DailyMed |
Generic Entry Opportunity Date for TALZENNA
Generic Entry Date for TALZENNA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for TALZENNA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer Inc | TALZENNA | talazoparib tosylate | CAPSULE;ORAL | 211651-001 | Oct 16, 2018 | RX | Yes | No | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | Y | ➤ Try a Free Trial | ||
| Pfizer Inc | TALZENNA | talazoparib tosylate | CAPSULE;ORAL | 211651-002 | Oct 16, 2018 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | Y | ➤ Try a Free Trial | ||
| Pfizer Inc | TALZENNA | talazoparib tosylate | CAPSULE;ORAL | 211651-001 | Oct 16, 2018 | RX | Yes | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Pfizer Inc | TALZENNA | talazoparib tosylate | CAPSULE;ORAL | 211651-002 | Oct 16, 2018 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Pfizer Inc | TALZENNA | talazoparib tosylate | CAPSULE;ORAL | 211651-001 | Oct 16, 2018 | RX | Yes | No | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | Y | ➤ Try a Free Trial | ||
| Pfizer Inc | TALZENNA | talazoparib tosylate | CAPSULE;ORAL | 211651-001 | Oct 16, 2018 | RX | Yes | No | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | Y | ➤ Try a Free Trial | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
International Patents for TALZENNA
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Denmark | 2767537 | ➤ Try a Free Trial |
| Singapore | 193842 | ➤ Try a Free Trial |
| European Patent Office | 2630146 | ➤ Try a Free Trial |
| World Intellectual Property Organization (WIPO) | 2012054698 | ➤ Try a Free Trial |
| Australia | 2009279944 | ➤ Try a Free Trial |
| Taiwan | I557123 | ➤ Try a Free Trial |
| Country | Document Number | Estimated Expiration |
